Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Closed well above VWAP and all the major moving averages. That's gotta get some attention on scanners, no? lol Healthy, green drinks for everyone!
I almost doubled up today - have way more shares than I intended, but the facts here speak for themselves. I'm just gonna have to miss some other runners and be patient here. I see .03-.04 shortly, with much more following whatever news may be headed our way. Gotta get rid of that stop sign asap!
Need to break and hold above that .0040 high.
Can we all just agree the floor is solid at .0021 so they can stop testing it? LOL - let's Go!
CORRECTION TO DL - CURRENT O/S 750,957,283
Ought to make it go straight up!
Are they in or going to get into the Rheumatoid Arthritis field? That would be awesome! Such a painful and destructive auto-immune disease.
right now into tens of BILLIONS of new shares
For new eyes:
If you are here for more than crumbs and cookies and think this might be a good LT hold, I linked some information to the field of regenerative medicine in the post below.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160605877
By far, and cutting edge technology sure to get RMAT after entering clinical trial:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expedited-programs-regenerative-medicine-therapies-serious-conditions
Regenerative Medicine Advanced Therapy Designation
An investigational drug is eligible for RMAT designation if:
• It meets the definition of regenerative medicine therapy (see section II of this document);
Contains Nonbinding Recommendations
6
• It is intended to treat,9 modify, reverse, or cure10 a serious condition; and
• Preliminary clinical evidence indicates that the regenerative medicine therapy has the potential to address unmet medical needs for such condition.
Advantages of the RMAT designation include all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with FDA (see Comparison of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation table, which sets forth key similarities and differences between breakthrough therapy designation and RMAT designation). Section 506(g)(5) of the FD&C Act specifies that these early interactions may be used to discuss potential surrogate or intermediate endpoints to support accelerated approval (see section III.E. in this guidance).
Regarding the preliminary clinical evidence to demonstrate the potential of a regenerative medicine therapy to address unmet medical needs, we generally expect that such evidence would be obtained from clinical investigations specifically conducted to assess the effects of the therapy on a serious condition. Such clinical investigations, particularly at the initial stages of product development, may not always be prospective clinical trials with a concurrent control. In some cases, clinical evidence obtained from clinical investigations with appropriately chosen historical controls may provide sufficient preliminary clinical evidence of the potential to address an unmet medical need. In other cases, preliminary clinical evidence could come from well-designed retrospective studies or clinical case series that provide data systematically collected by treating physicians. Such clinical evidence may be from studies conducted outside of the United States (Ref. 3). In any case, it is essential that the preliminary clinical evidence be generated using the product11 that the sponsor intends to use for clinical development.
When determining whether the preliminary clinical evidence is sufficient to support RMAT designation, CBER intends to consider factors, including but not limited to: the rigor of data collection; the consistency and persuasiveness of the outcomes; the number of patients or subjects, and the number of sites, contributing to the data; and the severity, rarity, or prevalence of the condition. In addition, CBER intends to consider the potential that bias (e.g., bias in the study design, treatment assignment, or outcome assessment) may be a factor in the evidence provided in support of RMAT designation. CBER will review the preliminary clinical evidence in each designation request, and will make designation decisions on a case-by-case basis. As opposed to breakthrough therapy
9 As described in section III.A.2 of the Expedited Programs Guidance (Ref. 2), FDA considers a drug to be intended to treat a serious condition when the drug is intended to have an effect on a serious condition, or a serious aspect of a condition, such as a direct effect on a serious manifestation or symptom of a condition.
10 This guidance uses the term “treat” to refer to the terms treat, modify, reverse, and cure, as used in section 506(g) of the FD&C Act.
11 FDA acknowledges that the issue of manufacturing changes is complex; however, manufacturing changes and product comparability are beyond the scope of this guidance. Manufacturing changes made to products during the development program would not necessarily preclude initial RMAT designation or cause RMAT designation to be rescinded. Such considerations will be made on a case-by-case basis.
Contains Nonbinding Recommendations
7
designation, the RMAT designation does not require evidence to indicate that the drug may offer a substantial improvement over available therapies. As with breakthrough therapy designation, an RMAT designation is not the same as an approval and does not change the statutory standards for demonstration of safety and effectiveness needed for marketing approval.12
The following are hypothetical examples of preliminary clinical evidence that CBER would consider sufficient to demonstrate a product has the potential to address unmet medical needs in those with a serious condition:
• In a single-arm, open-label study conducted in a center treating patients with severe and extensive skin burns, use of allogeneic keratinocyte- and fibroblast-based cell therapy is associated with rapid and substantial wound re-epithelialization of deep partial thickness burns in the majority of treated wounds.
• In a phase 2, dose-finding study, intra-myocardial administration of allogeneic human mesenchymal precursor cells to patients with advanced chronic heart failure refractory to available medical therapies is associated with dose-dependent improvement in several physiological measurements of left ventricular performance.
In order to apply for RMAT designation, a sponsor should submit a request to CBER either with a new investigational new drug application (IND) or in an IND amendment. CBER will not accept requests for RMAT designation for INDs that are inactive or on clinical hold. Additionally, FDA will not further process a pending RMAT designation request for an IND that is placed on inactive or hold status while the designation request is under review. If you submit an RMAT designation request as an amendment to your IND, the cover letter should specify that the submission contains an RMAT designation request. The request should be in bold, uppercase letters as follows: REQUEST FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION. If the request is submitted with an initial IND, the cover letter should specify that the submission contains both an initial IND and a request for RMAT designation. The request should be in bold uppercase letters as follows: INITIAL INVESTIGATIONAL NEW DRUG SUBMISSION and REQUEST FOR REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION.
In general, such a request should contain a concise summary of information that supports the RMAT designation, including:
12 FDA’s SOPP (Standard Operating Policy and Procedure) 8212, entitled “Management of Breakthrough Therapy-Designated Products: Sponsor Interactions and Status Assessment Including Rescinding” (Ref. 4), explains that breakthrough therapy designation is not the same as an approval and does not change the statutory standards for marketing approval.
Contains Nonbinding Recommendations
8
• A description of the investigational product, including a rationale for the investigational new drug meeting the definition of a regenerative medicine therapy;
• A discussion to support that the disease or condition, or the aspect of the disease or condition, that the product is intended to treat is serious;
• A summary of the risks and benefits associated with the therapies, if any, currently available for this condition;
• A description of the unmet medical need that the product has the potential to address; and
• The preliminary clinical evidence that the product has the potential to address the specified unmet medical need for this serious condition.
A request for designation as an RMAT should describe the preliminary clinical evidence supporting designation. A description of the preliminary clinical evidence should include, for example, the conditions for product administration, outcome assessment, and patient monitoring; a description of the patients and their outcomes, including the number of patients who have received the drug; and the design, conduct, and analyses of any clinical investigations.
No later than 60 calendar days after receipt of the designation request, CBER will notify the sponsor as to whether the regenerative medicine therapy has received the RMAT designation. If CBER determines that the regenerative medicine therapy does not meet the criteria for RMAT designation, CBER will include a written description of the rationale for the determination. As with other expedited development programs, if RMAT designation has been granted but, later in development, the product no longer meets the qualifying criteria, then CBER may rescind the RMAT designation. This is because FDA needs to focus its resources on RMAT product development programs that continue to meet the program’s qualifying criteria.
Thanks! CELZ gonna make the insiders and the longs some serious money soon.
Of course, one would be hard pressed to any find evidence supporting Dragon_Lady's claims:
3) They issue vapid PR HYPE ABOUT NOTHING and PAY A PROMOTION CREW AND RUN A MINI P&D as we saw them do since 12/28 till yesterday's COLLAPSE which was 30 ma MILLION shares being dumped by insiders aka the cons !
They sell in blocks of probably 500K at a time until each pile of 10 MILLION SHARES is gone - AT THE PEAK OF THE PUMP which is the collapse to .02X yesterday after peaking at .04X when they DUMPED HARD !
Suggestions don't stand up in any court, including the court of public opinion. Unless there is strong evidence, the theory being put forth that the three insiders exercised warrants and then dumped them immediately at or near the top of this so-called "pump" is simply groundless, baseless, flawed, and . . . shitty! LOL
From the looks of it,
They most certainly did exercise the warrants to purchase 10M shares each.
So, how much did they pay for each share purchased?
What was the exercise price of the warrants?
Warbington (CEO) acquired 19.7M shares in June, and 42,328,042 shares back in September. The company acquired a similar number in September also.
I doubt Warbington dumped all 62M of his shares at .04 for a paltry $2.48M . . . I think he's probably looking for a bigger payday.
It really helps to actually read the filings and see what happened. Really.
3 officers converted warrants for 10M shares each at .004 on 12/28
I'd like to wish each of you and your family a Happy New Year. May it be the best we've all had yet. May the markets let gold fall like rain for longs and shorts. May we all be healthy and have lots of love in our lives.
We've got a good one here! Be safe out there tonight! Peace.
I'd like to wish each of you and your family a Happy New Year. May it be the best we've all had yet. May the markets let gold fall like rain for longs and shorts. May we all be healthy and have lots of love in our lives.
We've got a good one here! Be safe out there tonight! Peace.
I think we've paid our dues at .0021. Floor is solid there, so let's get on with it!
The FDA and Regenerative Medicine:
2017
https://www.fda.gov/news-events/press-announcements/fda-announces-comprehensive-regenerative-medicine-policy-framework
With CELZ insiders and pre loaders DUMPING shares below the bid
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160562529
Gotta love those who help us the most . . . Happy New Year, DL!
Was kinda expecting a PR in conjunction with name/symbol change, but they may wait until Monday - new year, fresh energy, new investors. Holding up on .21 pretty well.
And no other company has ever done a reverse split and then become successful on the back of the research they are doing/have done? None?
look at trades.
Personalized (designer/genomic) medicine - read up on it this weekend once you're sober . . . $CELZ
2013 - https://newsinhealth.nih.gov/2013/12/personalized-medicine
2014 - https://pubmed.ncbi.nlm.nih.gov/25059740/
2015 - https://www.geneticsupport.org/genetics-personalized-medicine/
2016 - https://medcitynews.com/2016/06/biotech-revolutionizing-personalized-medicine/
2017 - https://medicalfuturist.com/top-companies-genomics/
2018 - https://healthitanalytics.com/features/what-are-precision-medicine-and-personalized-medicine
2019 - https://www.akc.org/expert-advice/health/personalized-medicine-for-dogs/
2020 - https://www.mayoclinic.org/healthy-lifestyle/consumer-health/in-depth/personalized-medicine/art-20044300
https://www.chop.edu/centers-programs/division-human-genetics
https://www.precisionnanosystems.com/workflows/genetic-medicine
https://www.geneticsupport.org/genetics-personalized-medicine/
https://www.nanalyze.com/2017/11/8-startups-using-ai-for-personalized-health/
This CELZ share selling SCAM will be dumping Megga BLOCK BUSTER SHARES!
Are the stocks telling you this or are you listening to people on the boards without doing your own thorough Due Diligence, which means reading hundreds of pages of rather 'boring' stuff to find the hidden truths that make or break a company? Stocks seldom speak.
Be Aware! Much unethical going on......
The basic premise at work here is the same premise at work behind runners like CEL Z, which ran on news of clinical results that showed the liver can be restored by engineering a patient's own stem cells to do the work: designer medicine. It is becoming a "thang" if you haven't noticed! VITX offers you a book that shows how your specific DNA guides what you should eat, drink, how you should exercise, what diseases to look out for, etc.
How was the dilution
Also, if we can develop a vaccine in less than one year and run it through all phases to approval, I think the approval landscape is going to change radically over the next year or so. The "it takes 10 years to develop a drug" paradigm has been broken. Given that there were many people working diligently to get the vaccine built, the fact remains: it did not take ten years, or even one year. The paradigm is broken. If these vaccine companies can do it, why can't someone else? Oh, wait . . . the FDA . . . almost forgot . . .
CDEL must have Jesus working for him . . . multiplying those little 10K shares on the ask into millions . . .
Two things make this special:
1. Individualized genetically engineered solutions
2.
The number of shares outstanding of the registrant’s common stock on November 6, 2020, was 577,128,087
I know. I've always found it interesting that when the "CEO" or "insiders" is/are thought to be doing something, the SEC is called on, but when individuals are clearly doing something of the same nature as the accused, it seems to not quite reach the level of "crime." LOL